You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百誠醫藥(301096.SZ):已立項尚未轉化的自主研發項目250-300項
格隆匯 01-18 18:00

格隆匯1月18日丨百誠醫藥(301096.SZ)於近期接受特定對象調研,就“公司自主立項的產品有多少個,是哪些方向的?”,公司回覆稱,公司已立項尚未轉化的自主研發項目250-300項,客户接受度高,公司的科學立項委員會綜合考慮藥品的疾病領域、技術壁壘、開發時間、市場前景與費用等多個因素,率先對項目立項並着手研發,確保公司能夠儲備眾多前景良好、供應短缺、具有一定技術壁壘的藥物品種,在研產品重點包括吸入製劑、緩控釋製劑、透皮給藥製劑及細粒劑等高端仿製藥。等待技術開發到一定階段,工藝相對成熟後,實現前述在研項目在任意節點包括實驗室研究、小試、中試、三批工藝驗證、臨牀試驗、註冊申報、獲取批件實現成果轉化,結合客户的需求而向客户推薦,推薦成功後接受客户委託繼續提供研發服務。2023年上半年,自主研發技術成果轉化收入1.9億元,同比增長約175%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account